Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

Holbrook E. Kohrt, … , Lieping Chen, Ronald Levy


Retraction

Citation for this retraction: J Clin Invest. 2019;129(6):2595. https://doi.org/10.1172/JCI129688
Stanford University School of Medicine recently notified the JCI of concerns regarding Figure 4, A and C, and indicated that the original source data for these figures could not be located. In accordance with the institutional recommendation, the JCI is retracting this article.

Find the latest version:

http://jci.me/129688/pdf
Retraction

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer


Citation for this retraction: J Clin Invest. 2019;129(6):2595. https://doi.org/10.1172/JCI129688.

Stanford University School of Medicine recently notified the JCI of concerns regarding Figure 4, A and C, and indicated that the original source data for these figures could not be located. In accordance with the institutional recommendation, the JCI is retracting this article.

Retraction

Targeting CD137 enhances the efficacy of cetuximab


Citation for this retraction: J Clin Invest. 2019;129(6):2595. https://doi.org/10.1172/JCI129689.

Stanford University School of Medicine recently notified the JCI of concerns regarding Figure 4, B, C, and E, Figure 5, B, D, and F, and Figure 6B and indicated that the original source data for these figures could not be located. In accordance with the institutional recommendation, the JCI is retracting this article.